UBS downgraded Par Pharmaceutical (NYSE: PRX) from Buy to Neutral.
This article: 52 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE